Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1442 • ACR Convergence 2025
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Ayumu Sugiura³, Jay Tang¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³, Paresh Thakker¹ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: As a chronic inflammatory disease, PsA is marked by cartilage and bone turnover and articular inflammation. Accordingly, elevated levels of inflammation and bone metabolism…
Abstract Number: 1711 • ACR Convergence 2025
Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis
Andrew McGucken¹, Flavia Sunzini², Kristian Stefanov¹, Joel Parkinson¹, Salim Al-Wasity¹, John McLean¹, Gordon Waiter³, Stefan Siebert¹ and Neil Basu⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Glasgow University, Glasgow, United Kingdom, ³University of Aberdeen, Aberdeen, United Kingdom, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Fatigue is a pervasive and burdensome symptom for people with psoriatic arthritis (PsA). The mechanisms underlying PsA related fatigue are unknown. In other clinical…
Abstract Number: 2203 • ACR Convergence 2025
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Arshdeep Waring¹, Sofia Rieger-Torres², Jeremiah Tan³, Viktoria Pavlova⁴ and Neda Amiri⁵, ¹University of British Columbia, Abbotsford, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McMaster University, Ancaster, ON, Canada, ⁵University of British Columbia, North Vancouver, BC, Canada
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as ixekizumab and secukinumab, are increasingly used in the treatment of seronegative inflammatory arthritis, including psoriatic arthritis and axial spondyloarthritis.…
Abstract Number: 2339 • ACR Convergence 2025
Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Alen Zabotti¹, Joseph F Merola², Ulrich Mrowietz³, Philip J. Mease⁴, Laure Gossec⁵, mitsumasa kishimoto⁶, Michele Brunori⁷, Lichen Teng⁸, Dafna D. Gladman⁹ and Laura Coates¹⁰, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁵Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ⁶Kyorin University School of Medicine, Tokyo, Japan, ⁷Amgen Inc, Zurich, Switzerland, ⁸Amgen Inc., Thousand Oaks, ⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Data on disease progression and joint involvement patterns in early oligoarticular (oligo) PsA are sparse. In the FOREMOST study (NCT03747939), apremilast (APR) decreased the…
Abstract Number: 2368 • ACR Convergence 2025
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease¹, Christopher Ritchlin², Laura Coates³, Alexa P. Kollmeier⁴, Bei Zhou⁵, Yusang Jiang⁵, Karen Bensley⁵, Koeun Im⁶, Rattandeep Batra⁷, Soumya Chakravarty⁸, Proton Rahman⁹ and Désirée Van Der Heijde¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²University of Rochester Medical Center, Canandaigua, NY, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁶Johnson & Johnson, Cambridge, MA, USA, Cambridge, MA, ⁷Johnson & Johnson, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with active psoriatic arthritis (PsA) are at risk of irreversible joint damage that may significantly impact quality of life. Guselkumab (GUS), a fully…
Abstract Number: 2691 • ACR Convergence 2025
Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
Pankti Mehta¹, Mu Yang², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Richard Cook², Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University of Waterloo, Waterloo, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Overweight and obesity is associated with poor outcomes in Psoriatic Arthritis (PsA), with reduced odds of achieving minimal disease activity (MDA). Whether this effect…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…
Abstract Number: 0532 • ACR Convergence 2025
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
Antonio Tonutti¹, Saverio D'Amico², Pierandrea Morandini², Cosimo Faeti², Elisa Barone¹, Nicoletta Luciano¹, Victor Savevski² and Carlo Selmi³, ¹Humanitas University, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano, Italy, ³Humanitas University, Milan, Italy
Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…
Abstract Number: 0559 • ACR Convergence 2025
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Javier R Godo¹, Christopher EM Griffiths², Miguel A. González-Gay³, Andreas Clemens⁴, Cynthia Vizcaya⁴, Lara Gómez⁵ and Nehal N Mehta⁶, ¹Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, ²Centre for Dermatology Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK and Department of Dermatology, King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom, ³Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Farmaceutica, Madrid, Spain, ⁶The George Washington University School of Medicine and Health Sciences, Washington DC
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with increased risk of cardiovascular (CV) disease driven by chronic systemic inflammation, with IL-17A…
Abstract Number: 0583 • ACR Convergence 2025
Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
Raquel Granados¹, Jesús Eduardo Martín Salazar², María Ángeles Puche-Larrubia³, Pedro Ortiz Buitrago⁴, María Dolores López-Montilla⁵, Jerusalén Calvo⁶, Rafaela Ortega-Castro⁷, Montserrat Romero-Gómez⁸, Alejandro Escudero-Contreras⁹, Nuria Barbarroja¹⁰ and Clementina López Medina¹¹, ¹Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, ²Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁸Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ⁹Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Previous studies have identified subgroups of patients with psoriatic arthritis (PsA) based on the severity of the disease [1,2]. However, no analysis to date…
Abstract Number: 1303 • ACR Convergence 2025
Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Xuemei Tang, Yuting Zhou, Yuxiao Chen, Xinglin Wu and Qiang Luo, Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic)
Background/Purpose: A balanced diet can prevent diseases and promote physical and mental health. Accumulating evidence shows that fruits and vegetables (F&Vs) intake is associated with…
Abstract Number: 1443 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
Iain McInnes¹, Koji Kato², Marina Magrey³, Joseph Merola⁴, mitsumasa kishimoto⁵, Derek Haaland⁶, Ivan Lagunes⁷, Laura Coates⁸, Yanxi Liu⁹, Erin Mancl¹⁰, Bhumik Parikh¹¹ and Charles Phillips¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Abbvie. Inc, North Chicago, IL, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶The Waterside Clinic, Oro Medonte, ON, Canada, ⁷Abbvie Inc, North Chicago, IL, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁹Abbvie Inc, Florham Park, NJ, ¹⁰AbbVie, Chicago, IL, ¹¹AbbVie, Hillsborough Township, NJ, ¹²AbbVie Inc, Princeton, NJ
Background/Purpose: We evaluated safety and efficacy of upadacitinib (UPA) versus adalimumab (ADA) at week 260 (5-years) from the long-term extension of SELECT-PsA 1.Methods: Randomized patients…
Abstract Number: 1712 • ACR Convergence 2025
Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman¹, Nicolas Coudray², Xu Han², Morgan Grams², Eric Oermann², Aristotelis Tsirigos² and Jose Scher³, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease that affects both the skin and musculoskeletal system and is frequently associated with a heightened…
Abstract Number: 2233 • ACR Convergence 2025
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Caleb Marlin¹, Roopa Madhu², Erin Theisen³, Liz Bradshaw⁴, Ce Gao⁵, Thomas Eisenhaure⁶, Nicolas Sugiarto⁷, Accelerating Medicines Partnertship: Autoimmune and Immune Mediated Diseases⁸, Jill Buyon⁹, Michelle Petri¹⁰, Brad Rovin¹¹, Victoria Werth¹², Ellen M. Gravallese¹³, Jennifer Anolik¹⁴, Larry Moreland¹⁵, Laura Donlin¹⁶, Christopher Ritchlin¹⁷, Jose Scher¹⁸, Johann Gudjonsson¹⁹, Wilson Liao²⁰, Alexis Ogdie²¹, Caroline Shiboski²², A. Darise Farris¹, Alan Baer²³, Blake M. Warner²⁴, Jose Clemente²⁵, Adriana Heguy²⁶, Michael Brenner²⁷, Nir Hacohen²⁸, Joel Guthridge¹, Judith James¹, Soumya Raychaudhuri²⁹, Lam Tsoi¹⁹, Xiang Zhou³⁰, Joshua Welch³⁰, Rachael Clark³, ilya Korsunsky²⁹, Christopher Lessard¹ and Kevin Wei³¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Boston, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute, Boston, ⁸Multiple Institutions, Oklahoma City, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹The Ohio State University, Columbus, OH, ¹²University of Pennsylvania, Wynnewood, PA, ¹³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵University of Colorado, Denver, CO, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University of Rochester Medical Center, Canandaigua, NY, ¹⁸New York University School of Medicine, New York, NY, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰UCSF, San Francisco, CA, ²¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²²University of California San Francisco, San Francisco, CA, ²³Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Icahn School of Medicine at Mount Sinai, New York, NY, ²⁶NYU Grossman School of Medicine, New York, ²⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁸Broad Institute of MIT Harvard, Cambridge, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰University of Michigan, Ann Arbor, ³¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Autoimmune diseases affect more than 23.5 million Americans involving nearly every organ system of the human body. To identify shared, unique, and novel pathways…
Abstract Number: 2340 • ACR Convergence 2025
Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Alexander Garaiman¹, Sophia Massa¹, Elnaz Saeedi², Nicola Gullick³, William Tillett⁴, Raphaël Hurtubise¹, jean-guillaume letarouilly⁵ and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Personalizing care in early psoriatic arthritis (PsA) is challenging. We set out to identify predictors of one-year response on the PASDAS using AI-based methods…

« Previous Page
1
…
8
9
10
11
12
…
93
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].